CytRx Shares Higher

CytRx shares rose 10% on Thursday after the company said updated results from a phase 3 trial of aldoxorubicin in patients with relapsed and refractory soft tissue sarcomas continued to demonstrate significantly prolonged progression-free survival compared to standard treatments.

Moreover, the data show that aldoxorubicin can be dosed continuously with minimal to no cardiotoxicity.
“Taken together, these findings support aldoxorubicin’s potential as a superior anthracycline treatment for patients suffering with these highly complex and difficult to treat types of cancer,” said Sant Chawla, principal investigator for the trial.

Leave a Comment